LGD-4033
is a selective androgen receptor modulator
(SARMS), and a novel non-steroidal oral SARM that binds to AR with high
affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen
receptor
(AR) ligands that is tissue selective, developed to treat muscle
wasting
associated with cancer, acute and chronic illness and age-related
muscle loss.
LGD-4033 is expected to produce the therapeutic benefits of
testosterone with
improved safety, tolerability and patient acceptance due to
tissue-selective
mechanism of action and an oral route of administration.
LGD-4033, a novel nonsteroidal, oral selective androgen
receptor modulator, binds to the androgen receptor with high affinity
and
selectivity. It demonstrates anabolic activity in muscles,
anti-resorptive and
anabolic activity in bones and a robust selectivity for muscle and bone
versus
prostate and sebaceous glands.
Available Flavors:
not applicable (capsules)
Recommended
doses for recomping would be 5-8 mg a day
for 8 weeks.
COMPOSITION
Serving
Size: 1
Servings Per Container: 90
Amount
Per Serving:
LGD-4033
3mg
